A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melat... - 1 views
-
Nathan Goodyear on 01 Jun 18Average progression-free time and percentage of patients alive at 1 year was significantly higher in those using IL-2 and melatonin compared to chemotherapy in aggressive NSCLC. Of note, in this study, they used a repeat cycle of IL-2 and MLT as well as a once/week maintenance IL-2 and MLT.